The present Competitive Intelligence Report about Coagulation Factors provides a competitor evaluation in the field of plasma-derived and recombinant coagulation factors for topical or systemic administration to treat hereditary or acquired coagulation disorders as of October 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The market size of recombinant and plasma-derived coagulation factor products exceeded US$ 7.5 bln in 2008, the majority (US$ 5.5 bln) generated by recombinant proteins. Replacement of plasma-derived coagulation factors by marketed recombinant molecules is ongoing and will further increase by new recombinant coagulation factors in development. In light of ongoing expiration of substance patents, about 40 new recombinant coagulation factor projects are in the pipeline indicating a changing marketplace over the next decade. New players are competing and will challenge established manufacturers and marketers of coagulation factor products.

Apart from recombinant products, plasma-derived coagulation factors still play a considerable role, albeit bovine derived products are considerably being challenged by human recombinant and plasma-derivd products. Coagulation factors not only are being used for systemic treatment of hereditary coagulation factor deficiencies, but also for topical or systemic treatment of bleedings.

The report includes a compilation of current active projects in research and development of topical and systemic coagulation factors obtained by purification of human plasma or by recombinant DNA technology. In addition, the report lists company-specific R&D pipelines of coagulation factors. Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.
  

Index

• Coagulation Factor VIII
• Coagulation Factor IX
• Coagulation Factor VII
• Von Willebrand Factor (vWF)
• Fibrinogen
• Coagulation Factors V and XI
• Coagulation Factor X
• Coagulation Factor XIII
• Topical Fibrinogen and Thrombin Products
• Topical Thrombin Products
• Prothrombin Complex Concentrates
• Corporate Coagulation Factor Product and R&D Pipelines
• About La Merie

Corporate Coagulation Factor Product and R&D Pipelines

• Abraxis Biosciences
• Amsterdam Molecular Therapeutics
• Angiotech
• Apitope
• Asklepios Biopharmaceutical
• Baxter
• Bayer Schering Pharma
• Bio Products Laboratory (BPL)
• Biogen Idec
• Biotest
• Biovitrum
• Catalyst Biosciences
• China Biologic Products
• Crucell
• CSL
• Ethicon (J&J)
• Genzyme
• Green Cross
• Grifols
• GTC Biotherapeutics
• Haemacure
• Inspiration Biopharmaceuticals
• Intas Biopharmaceuticals
• Ipsen
• Jerini
• Kaketsuken
• Kamada
• Kedrion
• King Pharmaceuticals
• LFB
• Lipoxen
• Maxygen
• MDRNA
• MediVas
• Mochida Pharmaceutical
• National Bioproducts Institute (NBI)
• Nautilus Biotech (HanAll Pharmaceuticals)
• Nektar Therapeutics
• Neose Technologies
• Novo Nordisk
• Nycomed
• Octapharma
• Oxford Biomedica
• Pharming
• ProFibrix
• ProGenetics
• PROLOR Biotech
• Recoly
• Roche
• Sanquin
• Shanghai RAAS
• Sinobiomed
• SK Chemicals
• Talecris Biotherapeutics
• Thrombotargets
• VIRxSYS
• Wyeth
• Zymogenetics

About Competitor Analysis Series

The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Pages: 126
Release Date: October of 2009
Format: PDF
Product Code: LMCA0027